Healthcare Regulation (HIPAA)

As youth nicotine pouch use soars, Imperial Tobacco Canada calls for a crackdown on illicit sales. But is this a genuine public health plea or a masterful play to secure its market?

As Ontario doctors adopt AI to fight burnout, a new training program from OntarioMD tackles the urgent medico-legal and privacy risks head-on.

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.

With its $30M purchase of CareSeed, Sagility is betting on AI-driven analytics to move beyond compliance and redefine healthcare quality and financial outcomes.

As AI transforms healthcare, ECLAT Health Solutions secures the coveted HITRUST r2 certification, setting a new benchmark for data protection and trust.

For 17 years, Jeffrey Phillips helped California revoke professional licenses. Now, he's joined the defense. His move reveals a crucial shift in the high-stakes world of regulatory law.

For millions, the 'why' behind infertility remains a mystery. New genomic mapping tech is finally providing answers, changing the landscape of family planning.

Sweeping data from EHA 2026 shows Syndax's Revuforj achieving remarkable success across leukemia settings, signaling a new standard of care and a major market coup.

A key deal locking in generic drug prices is extended, promising billions in savings for healthcare and providing crucial stability for a fragile industry.

Amid a national teacher crisis, Dr. Veronica Bradley's "Why Stay?" shifts the focus from attrition to retention, commercializing a new theory of resilience.

Dissecting the Med-Metrix acquisition of CanAide. A strategic move by private equity to capture the booming RCM market by tackling provider costs and patient access.

A new Florida venture embeds sleep apnea treatment into cardiology care, a model that could reshape patient outcomes and Vivos Therapeutics' market strategy.

A market set to triple, driven by gene-level therapies, promises a revolution for children with rare epilepsies. But can our systems deliver this hope?

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

A new partnership between software specialist Cosylab and hardware innovator Heron aims to overcome the final hurdles in deploying a promising cancer therapy worldwide.

Health Canada's Priority Review for a new Duchenne muscular dystrophy drug signals hope for patients and a strategic test of Canada's rare disease market.

A UK firm's regulatory milestone is more than just compliance; it's a strategic masterclass in building the resilient systems needed to fight food allergies.

A groundbreaking partnership between Servier and n-Lorem Foundation blends pharma R&D muscle with non-profit agility to develop ASO therapies for the rarest of diseases.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.